Kaplan-Meier analyses confirmed that MYBL2 expression was a robust marker of poor patient outcomes in multiple tumor types, including lung adenocarcinoma (LUAD, n = 128 patients/arm), isocitrate dehydrogenase (IDH)-mutant lower grade glioma (IDHMUT LGG, n = 104 patients/arm), pancreatic adenocarcinoma (PAAD, n = 44 patients/arm), uterine corpus endometrial carcinoma (UCEC, n = 132 patients/arm), and sarcoma (SARC, n = 63 patients/arm) (Figure 1B, Supplementary Tables S1 and S2). This evidence concerns the gene MYBL2 and pancreatic adenocarcinoma.